Analysts Conflicted on These Healthcare Names: 23andMe Holding (ME), Tenet Healthcare (THC) and Revvity (RVTY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on 23andMe Holding (ME – Research Report), Tenet Healthcare (THC – Research Report) and Revvity (RVTY – Research Report).

23andMe Holding (ME)

Citi analyst David Lebovitz maintained a Hold rating on 23andMe Holding yesterday and set a price target of $1.75. The company’s shares closed last Monday at $0.77, close to its 52-week low of $0.61.

According to TipRanks.com, Lebovitz is a 1-star analyst with an average return of -2.3% and a 47.0% success rate. Lebovitz covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, BioMarin Pharmaceutical, and Intellia Therapeutics.

23andMe Holding has an analyst consensus of Moderate Buy, with a price target consensus of $3.88.

See today’s best-performing stocks on TipRanks >>

Tenet Healthcare (THC)

According to TipRanks.com, Cassorla has 0 stars on 0-5 stars ranking scale with an average return of -23.7% and a 23.9% success rate. Cassorla covers the Healthcare sector, focusing on stocks such as Clover Health Investments, Community Health, and Universal Health.

Currently, the analyst consensus on Tenet Healthcare is a Strong Buy with an average price target of $90.92, representing a 69.2% upside. In a report issued on October 20, Wells Fargo also maintained a Buy rating on the stock with a $71.00 price target.

Revvity (RVTY)

According to TipRanks.com, Donnelly is a 3-star analyst with an average return of 1.8% and a 42.1% success rate. Donnelly covers the Healthcare sector, focusing on stocks such as Quest Diagnostics, Guardant Health, and Exact Sciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Revvity with a $123.30 average price target, implying a 52.2% upside from current levels. In a report issued on October 17, Goldman Sachs also maintained a Buy rating on the stock with a $120.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ME:

• 23andMe to Report FY2024 Second Quarter Financial Results
• 23andMe (NASDAQ:ME) Turns Attention to Genetic Disorders
• 23andMe discloses user accounts data breach
• 23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
• 23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program